Genesis
PeptidePharma was founded on February 5, 2007, as a collaborative joint venture of a group of partners coming from the pharmaceutical industry as well as the scientific research field.
A worldwide leader company
The main objective of this group of experts is to create a worldwide leader company in the development of new cutting-edge peptide-based drugs and molecules with pharmacological, diagnostic and cosmetic interest.
Moreover, our experience in encapsulation and controlled release of active principles allows us the development of biotechnological solutions for nanomedicine, by means of targeted nanoparticles releasing drugs and/or imaging compounds.
- PeptidePharma arises with the desire to create and develop more welfare and preserve life in a sustainable and respectful with the environment.
- PeptidePharma was founded with capital contributed by the partners, starting in economic activity in 2007.
- Its headquarters is located in Barcelona.
Team: Competence of the entrepreneurial team.
PeptidePharma laboratories will maintain a profiled strategy of sustained cooperation with other companies in the sector to enhance their entry into foreign markets and expand its product range.
PeptidePharma is collaborating with universities and research centers making projects of research and development within and outside Spain, enabling us the set up of cutting edge technologies that goes from the pharmaceutical world into cosmetics.
We have ongoing cooperation contracts to expand these partnerships in different sectors and markets. The company has enthusiasm, ability and dedication to complement the unstoppable growth with relevant corporate transactions.
But the essential element for the current and future success of PeptidePharma is undoubtedly its people, small but powerful group scientists: competent professionals committed to the mission of the company to be among the leaders in specialized segments of health care based to provide innovative and effective products and create value to the progress of humanity.
The use of techniques such as combinatorial chemistry, solid phase synthesis enables us to prepare hundreds of molecules at a time and in a cost effective way and also in combination with de novo rational design employing molecular modelling and docking. Our expertise in R&D follows a multidisciplinary approach that combines biochemistry, biotechnology, chemistry and pharmacy allows us to design of new pharmaceutical products or select the appropriate candidates that will be later developed for cosmetic applications. It should be emphasized our experience in the design of controlled drug release systems, as different kinds of liposomes and nanoparticles in order to target specific cells, avoid body fluid dispersion and protect labile ingredients.
The rigor in decision-making, innovation, teamwork and lifelong learning, the result of the application of the values of the company, are your best guarantee of progress.